sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_6132> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_6132> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB01165> ;
    a rdf:Statement ;
    rdfs:label "to reduce the development of drug resistant bacteria and maintain the effectiveness of ofloxacin tablets and other antibacterial drugs ofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy ofloxacin tablets are indicated for the treatment of adults with mild to moderate infections unless otherwise indicated caused by susceptible strains of the designated microorganisms in the infections listed below please see dosage and administration acute bacterial exacerbations of chronic bronchitis abecb haemophilus influenzae streptococcus pneumoniae because fluoroquinolones including ofloxacin have been associated with serious adverse reactions see warnings community acquired pneumonia haemophilus influenzae streptococcus pneumoniae uncomplicated skin and skin structure infections staphylococcus aureus streptococcus pyogenes or proteus mirabilis acute uncomplicated urethral and cervical gonorrhea neisseria gonorrhoeae warnings nongonococcal urethritis and cervicitis chlamydia trachomatis warnings mixed infections of the urethra and cervix chlamydia trachomatis neisseria gonorrhoeae warnings acute pelvic inflammatory disease chlamydia trachomatis neisseria gonorrhoeae warnings note if anaerobic microorganisms are suspected of contributing to the infection appropriate therapy for anaerobic pathogens should be administered uncomplicated cystitis citrobacter diversus enterobacter aerogenes escherichia coli klebsiella pneumoniae proteus mirabilis or pseudomonas aeruginosa because fluoroquinolones including ofloxacin have been associated with serious adverse reactions see warnings complicated urinary tract infections escherichia coli klebsiella pneumoniae proteus mirabilis citrobacter diversus pseudomonas aeruginosa prostatitis escherichia coli although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome efficacy was studied in fewer than 1 patients appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin therapy with ofloxacin may be initiated before results of these tests are known once results become available appropriate therapy should be continued as with other drugs in this class some strains of pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB01165> bl:category bl:Drug .
}